MedTrace Logo

Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.

NCT05389267 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2024-02-07

No results posted yet for this study

Summary

The study purpose is to evaluate the safety of T4090.

Conditions

Interventions

DRUG

Kinezodianone R hydrochloride

Eyedrops

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Laboratoires Thea

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-05
Primary Completion
2024-12-31
Completion
2024-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05389267 on ClinicalTrials.gov